Pimitespib: First Approval

2022/08/20 by Sheridan M. Hoy · 26 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Heat shock proteins research #Colorectal Cancer Treatments and Studies #Cancer, Hypoxia, and Metabolism

paper · doi:10.1007/s40265-022-01764-6

Citations

• Secondary KIT mutations: the GIST of drug resistance and sensitivity

Cited by

• Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
• Pharmacophore Model-Based Virtual Screening Workflow for Discovery of Inhibitors Targeting Plasmodium falciparum Hsp90. [europepmc]
• Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer. [europepmc]
• Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial. [europepmc]
• Hsp90 inhibition leads to an increase in surface expression of multiple immunological receptors in cancer cells. [europepmc]
• FRET Assays for the Identification of C. albicans HSP90-Sba1 and Human HSP90α-p23 Binding Inhibitors. [europepmc]
• Discovery of Disubstituted Carboranes as Inhibitors of Heat Shock Protein 90-Heat Shock Factor 1 Interaction. [europepmc]
• An update on the status of HSP90 inhibitors in cancer clinical trials. [europepmc]
• Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group. [europepmc]
• New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer. [europepmc]
• Extracellular heat shock protein 90 alpha (eHsp90α)'s role in cancer progression and the development of therapeutic strategies. [europepmc]
• Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies. [europepmc]
• Discovery of new Hsp90-Cdc37 protein-protein interaction inhibitors: in silico screening and optimization of anticancer activity. [europepmc]
• Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry. [europepmc]
• HSP90 N-terminal inhibition promotes mitochondria-derived vesicles related metastasis by reducing TFEB transcription via decreased HSP90AA1-HCFC1 interaction in liver cancer. [europepmc]
• Synthesis, Anticancer Screening, and In Silico Evaluations of Thieno[2,3- c ]pyridine Derivatives as Hsp90 Inhibitors. [europepmc]
• Chaperone directed heterobifunctional molecules circumvent KRAS G12C inhibitor resistance. [europepmc]
• Alvespimycin is identified as a novel therapeutic agent for diabetic kidney disease by chemical screening targeting extracellular vesicles. [europepmc]
• Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in Hepatoblastoma. [europepmc]
• The Cytotoxic Activity of Secondary Metabolites from Marine-Derived Penicillium spp.: A Review (2018-2024). [europepmc]
• Hsp90 pan and Isoform-Selective Inhibitors as Sensitizers for Cancer Immunotherapy. [europepmc]
• Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives. [europepmc]
• Small-molecule inhibitor of C‑terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cells. [europepmc]
• Targeting HER2-Positive HCC1954 Breast Cancer Cells by Novel Thiazole-Dihydrobenzisoxazoles: In-Depth Design, Synthesis and Initial In Vitro Study. [europepmc]
• Development of a chaperone-mediated protein degrader targeting ERK5 that efficaciously reduces tumor growth. [europepmc]
• Breaking the bonds: targeting protein dimerization for prostate cancer therapy. [europepmc]